共 50 条
- [31] Results of the safety and tolerability of ivaltinostat plus capecitabine in the phase 1b portion of a phase 1b/2, dose-escalation, randomized, multi-center study in the maintenance (maint) setting in patients with metastatic pancreatic adenocarcinoma (mPDAC).JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 666 - 666Walker, Evan JustinFountzilas, ChristosBorazanci, Erkut HasanShields, Anthony F.D'Olimpio, James ThomasHecht, J. RandolphTang, Shou-ChingMichelson, GlennLiganor, LornaCho, Sangsook AhnKo, Andrew H.
- [32] A Phase 1B Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FBS0701, a Novel Oral Iron Chelator for the Treatment of Chronic Iron Overload.BLOOD, 2010, 116 (21) : 853 - 854Rienhoff, Hugh Y., Jr.Viprakasit, VipTay, Lay H.Harmatz, PaulVichinsky, ElliottChirnomas, DeborahKwiatkowski, JanetTapper, Amy E.Porter, John B.Neufeld, Ellis J.
- [33] A Phase 1b, open-label study to evaluate the safety and tolerability of the putative remyelinating agent, liothyronine, in individuals with multiple sclerosisNEUROLOGY, 2019, 92 (15)Newsome, ScottShoemaker, ThomasTian, FanFitzgerald, KateBhargava, PavanSnoops, SarahCooper, DavidMammen, JenniferMowry, EllenCalabresi, Peter
- [34] A phase 1 single ascending dose study of the safety, tolerability and pharmacokinetics of CRV431JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E464 - E465Armas, DanielleSnyder, MichaelTrepanier, DanielUre, DarenGreytok, JillFoster, Robert
- [35] Safety, tolerability, and pharmacokinetics of BJT-778, a monoclonal antibody for treatment of chronic hepatitis B and chronic hepatitis D, following single ascending doses in healthy volunteersJOURNAL OF HEPATOLOGY, 2024, 80 : S811 - S811Gane, Edward J.Schwabe, ChristianSmith, PatrickWilleford, Courtney MocMoore, CaroleGrecko, RoyChu, KetingJavanbakht, HassanShulman, Nancy
- [36] Safety and effectiveness of HSK21542 for hemodialysis patients: a multiple ascending dose studyFRONTIERS IN PHARMACOLOGY, 2023, 14Pan, MingmingWang, GuihuaZhou, LiXu, YanYao, LiWu, ChaoqingMei, ChanglinZhao, ZhanzhengSun, DongGuan, TianjunChen, QinkaiShi, MingXu, HuiZeng, WeifangLi, FangqiongYan, RuiLiu, Bi-Cheng
- [37] Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose studyJOURNAL OF HEPATOLOGY, 2011, 54 (06) : 1130 - 1136Forestier, NicoleLarrey, DominiqueGuyader, DominiqueMarcellin, PatrickRouzier, ReginePatat, AlainSmith, PatrickBradford, WilliamsonPorter, StevenBlatt, LawrenceSeiwert, Scott D.Zeuzem, Stefan
- [38] Antiviral activity, pharmacokinetics and safety of the second-generation hepatitis B core inhibitor ABI-H2158 in Phase 1b study of patients with HBeAg-positive chronic hepatitis B infectionJOURNAL OF HEPATOLOGY, 2020, 73 : S125 - S125Agarwal, KoshNiu, JunqiDing, YanhuaGane, EdwardTuan NguyenAlves, KatiaEvanchick, MarcZayed, HanyHuang, QiKnox, StevenStamm, LuisaColonno, RichardHassanein, TarekKim, Dong JoonLim, Young-SukYuen, Man-Fung
- [39] SAFETY AND ANTIVIRAL EFFECT OF THE FARNESOID X RECEPTOR AGONIST EYP001 IN CHRONIC HEPATITIS B PATIENTS: A RANDOMISED PLACEBO-CONTROLLED PHASE 1b STUDYHEPATOLOGY, 2019, 70 : 442A - 443AErken, RobinAndre, PatriceRoy, EliseBarzic, NoelieGirma, HugoDarteil, RaphaelVonderscher, JackyScalfaro, PietroTangkijvanich, PisitFlisiak, RobertReesink, Henk W.
- [40] Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis CHEPATOLOGY RESEARCH, 2017, 47 (13) : 1429 - 1437Atsukawa, MasanoriTsubota, AkihitoKoushima, YoheiIkegami, TadashiWatanabe, KoujiShimada, NoritomoSato, ShinichiKato, KeizoAbe, HiroshiOkubo, TomomiArai, TaeangItokawa, NorioKondo, ChisaMikami, ShigeruAsano, ToruChuganji, YoshimichiMatsuzaki, YasushiIwakiri, Katsuhiko